Cerenome, Inc. (NASDAQ:CNSY) — Market Cap & Net Worth
Market Cap & Net Worth: Cerenome, Inc. (CNSY)
Cerenome, Inc. (NASDAQ:CNSY) has a market capitalization of $25.33 Million ($25.33 Million) as of August 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24438 globally and #5229 in its home market, demonstrating a -4.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cerenome, Inc.'s stock price $3.68 by its total outstanding shares 6883897 (6.88 Million). See CNSY equity financing ratio to understand what proportion of total assets are financed by equity.
Cerenome, Inc. Market Cap History: 2026 to 2026
Cerenome, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $25.33 Million to $25.33 Million (0.00% CAGR). Also see Cerenome, Inc. asset portfolio for a full breakdown of the balance sheet.
Cerenome, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cerenome, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CNSY stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNSY by Market Capitalization
Companies near Cerenome, Inc. in the global market cap rankings as of August 17, 2026. Also see Cerenome, Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
Key companies related to Cerenome, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #193 globally with a market cap of $128.19 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #341 globally with a market cap of $81.26 Billion USD.
- Samsung Biologics Co Ltd (KO:207940): Ranked #568 globally with a market cap of $48.56 Billion USD ( ₩71.66 Trillion KRW).
- Argen-X (BR:ARGX): Ranked #577 globally with a market cap of $47.46 Billion USD ( €40.60 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #193 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.19 Billion | $505.75 |
| #341 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $81.26 Billion | $803.48 |
| #568 | Samsung Biologics Co Ltd | KO:207940 | $48.56 Billion | ₩1548000.00 |
| #577 | Argen-X | BR:ARGX | $47.46 Billion | €730.20 |
Cerenome, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Cerenome, Inc.'s market cap moved from $25.33 Million to $ 25.33 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.33 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 17th, 2026 the market cap of Cerenome, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.33 Million USD |
| MoneyControl | $25.33 Million USD |
| MarketWatch | $25.33 Million USD |
| marketcap.company | $25.33 Million USD |
| Reuters | $25.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more